- TWD4.25bn
- TWD6.62bn
- TWD1.76bn
- 13
- 24
- 55
- 16
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.14 | ||
| Price to Tang. Book | 3.16 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.42 | ||
| EV to EBITDA | 44.12 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -0.36% | ||
| Return on Equity | 0.31% | ||
| Operating Margin | -0.76% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 2,172.92 | 1,668.59 | 1,849.92 | 2,210.59 | 1,755.57 | 2,098 | n/a | -2.64% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -38.3 | -42.9 | +39.21 | +6.19 | -93.35 | +1072.41 | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bionime Corporation is a Taiwan-based company principally engaged in the manufacture and distribution of blood glucose monitoring products. The Company's main products include blood glucose monitoring devices and blood glucose testing chips. Its products are applied in the testing and monitoring of blood glucose density. The Company distributes its products mainly to overseas markets, including Europe, Asia, the Americas and others.
Directors
- Chun Huang CHM
- Taixiong Jiang DGM
- Shixiong Huang DGM
- Zhenteng Xu DGM
- Xiexun Zhong DGM
- Huizhen Chen OTH
- Yawen Chen OTH
- Liren Hu DRC
- Ganren Cai IND
- Lizhen Guo IND
- Xueyu Lu IND
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 14th, 2003
- Public Since
- August 26th, 2009
- No. of Employees
- 671
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Taiwan Stock Exchange- Shares in Issue
- 60,942,394
- Address
- No.100, Section 2, TAICHUNG, 402
- Web
- https://www.bionime.com/
- Phone
- +886 423692388
- Contact
- Chun Huang
- Auditors
- KPMG LLP
Upcoming Events for 4737
Similar to 4737
Apex Biotechnology
Taiwan Stock Exchange
Wellell
Taiwan Stock Exchange
CHC Healthcare
Taiwan Stock Exchange
Excelsior Medical Co
Taiwan Stock Exchange
Lead Data
Taiwan Stock Exchange
FAQ
What is the Bionime share price?
As of Today at 19:03 UTC, shares in Bionime are trading at TWD69.70. This share price information is delayed by 15 minutes.
How has the Bionime share price performed this year?
Shares in Bionime last closed at TWD69.70 and the price had moved by -8.41% over the past 365 days. In terms of relative price strength the Bionime share price has underperformed the FTSE Developed Asia Pacific Index by -7.78% over the past year.
What are the analyst and broker recommendations for Bionime?
The overall consensus recommendation for Bionime is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Bionime dividend yield?
The Bionime dividend yield is 2.87% based on the trailing twelve month period.
Does Bionime pay a dividend?
Last year, Bionime paid a total dividend of TWD2.00, and it currently has a trailing dividend yield of 2.87%. We do not have any data on when Bionime is to next pay dividends.
When does Bionime next pay dividends?
We do not have data on when Bionime is to next pay dividends. The historic dividend yield on Bionime shares is currently 2.87%.
How do I buy Bionime shares?
To buy shares in Bionime you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Bionime?
As of the previous close price of TWD69.70, shares in Bionime had a market capitalisation of TWD4.25bn.
Where are Bionime shares listed?
Here are the trading details for Bionime:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 4737
What kind of share is Bionime?
Based on an overall assessment of its quality, value and momentum Bionime is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Bionime share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Bionime share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bionime. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -23.76%.
As of the last closing price of TWD69.70, shares in Bionime were trading -6.76% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Bionime PE Ratio?
The Bionime PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD69.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Bionime?
Bionime's management team is headed by:
- Chun Huang - CHM
- Taixiong Jiang - DGM
- Shixiong Huang - DGM
- Zhenteng Xu - DGM
- Xiexun Zhong - DGM
- Huizhen Chen - OTH
- Yawen Chen - OTH
- Liren Hu - DRC
- Ganren Cai - IND
- Lizhen Guo - IND
- Xueyu Lu - IND